AccScience Publishing / TD / Volume 3 / Issue 1 / DOI: 10.36922/td.2290

Profiling energy metabolism in normal bladder tissue and non-muscle-invasive bladder cancer cases of different histological grades

Guilherme Prado Costa1,2 Petra Karla Böckelmann1 Renato Prado Costa2 Carlos Hermann Schaal2 Fernando César Sala2 André Pereira Vanni2 Leandro Luiz Lopes de Freitas3 João Carlos Cardoso Alonso1,4 Gabriela Cardoso de Arruda Camargo1 Gabriela de Oliveira1 Bianca Ribeiro de Souza5 Athanase Billis3 Wagner José Fávaro1*
Show Less
1 Laboratory of Urogenital Carcinogenesis and Immunotherapy (LCURGIN), Universidade Estadual de Campinas (UNICAMP), Campinas City, São Paulo State, Brazil
2 Department of Urology, Amaral Carvalho Hospital (HAC), Jaú City, São Paulo State, Brazil
3 Department of Pathology, Medical School, Universidade Estadual de Campinas (UNICAMP), Campinas City, São Paulo State, Brazil
4 Department of Urology, Paulínia Municipal Hospital, Paulínia City, São Paulo State, Brazil
5 Department of Obstetrics and Gynecology, OVCARE, University of British Columbia, Vancouver, British Columbia, Canada
Tumor Discovery 2024, 3(1), 2290
Submitted: 22 November 2023 | Accepted: 9 January 2024 | Published: 19 March 2024
© 2024 by the Author (s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( )

Bladder cancer (BC) stands as the second most common urinary tract malignancy. Recent years have witnessed a growing interest in investigating energy metabolism to help with better understanding the energy sources harnessed by tumor cells. The aims of the present study are to feature and compare cell energy metabolism profiles among different histological grades of non-muscle-invasive BC (NMIBC) by adjusting their bioenergetic cellular indexes based on the specific tumor types. Forty urinary bladder tissue samples from patients both with and without a diagnosis of urothelial lesions were collected. Subsequently, samples were categorized into four groups comprising ten samples each, namely: normal (no urothelial lesions) group, low-grade pTa group, high-grade pTa group, and high-grade pT1 group. These tissue samples were examined by means of immunohistochemistry and Western blotting to assess proteins involved in cell energy metabolism. Based on the current findings, the normal and low-grade pTa groups presented clear preference for the oxidative phosphorylation pathway; consequently, they recorded high bioenergetic cellular index. On the other hand, both the high-grade pTa and pT1 groups presented proclivity towards the glycolytic pathway. These observations, mainly those associated with the bioenergetic cellular index, hold promising clinical relevance in the management of BC. Given the often aggressive and potentially debilitating nature of treatments applied to this neoplasia type, the current study offers invaluable insights on this topic and emphasizes changes in the bioenergetic cellular index at different NMIBC grades, which could serve as potential markers for both the diagnosis and prognosis of NMIBC patients.

Bladder cancer
Energy metabolism
Bioenergetic cellular index
Cancer metabolism
This research was funded by the São Paulo Research Council (FAPESP grant numbers: 2014/11866-1; 2014/12047-4; 2018/10052-1; 2020/03419-6), and the Brazilian National Council for Scientific and Technological Development (CNPq grant numbers: 552120/2011-1; 312396/2021-0).
  1. Celada Luis G, Albers Acosta E, De la Fuente H, et al. A comprehensive analysis of immune response in patients with non-muscle-invasive bladder cancer. Cancers (Basel). 2023;15:1364. doi: 10.3390/cancers15051364


  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424. doi: 10.3322/caac.21492


  1. Allard P, Bernard P, Fradet Y, Têtu B. The early clinical course of primary Ta and T1 bladder cancer: A proposed prognostic index. Br J Urol. 1998;81:692-698. doi: 10.1046/j.1464-410x.1998.00628.x


  1. Lamm D, Persad R, Brausi M, et al. Defining progression in nonmuscle invasive bladder cancer: It is time for a new, standard definition. J Urol. 2014;191:20-27. doi: 10.1016/j.juro.2013.07.102


  1. Babjuk M, Burger M, Capoun O, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81(1):75-94. doi: 10.1016/j.eururo.2021.08.010


  1. Sylvester RJ, Van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466-465, discussion 475-477. doi: 10.1016/j.eururo.2005.12.031


  1. Van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: From epidemiology to treatment strategy. Eur Urol. 2009;56:430-442. doi: 10.1016/j.eururo.2009.06.028


  1. Cote RJ, Chatterjee SJ. Molecular determinants of outcome in bladder cancer. Cancer J Sci Am. 1999;5:2-15.


  1. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: Prostate and bladder tumours. Eur Urol. 2016;70:106-119. doi: 10.1016/j.eururo.2016.02.028


  1. Kunju LP, You L, Zhang Y, Daignault S, Montie JE, Lee CT. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens. J Urol. 2008;180:1928-1932. doi: 10.1016/j.juro.2008.07.056


  1. Semeniuk-Wojtaś A, Poddębniak-Strama K, e, et al. Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer. Cancer Immunol Immunother. 2023;72(7):1971-1989. doi: 10.1007/s00262-023-03376-9


  1. Domblides C, Lartigue L, Faustin B. Control of the antitumor immune response by cancer metabolism. Cells. 2019;8(2):104. doi: 10.3390/cells8020104


  1. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144:646-674. doi: 10.1016/j.cell.2011.02.013


  1. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7:11-20. doi: 10.1016/j.cmet.2007.10.002


  1. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 2009;324:1029-1033. doi: 10.1126/science.1160809


  1. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11:85-95. doi: 10.1038/nrc2981


  1. Cuezva JM, Krajewska M, De Heredia ML, et al. The bioenergetic signature of cancer: A marker of tumor progression. Cancer Res. 2002;62:6674-6681.


  1. Isidoro A, Martínez M, Fernández PL, et al. Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. Biochem J. 2004;378:17-20. doi: 10.1042/BJ20031541


  1. Vallejo CG, Cruz-Bermudez A, Clemente P, Hernandez- Sierra R, Garesse R, Quintanilla M. Evaluation of mitochondrial function and metabolic reprogramming during tumor progression in a cell model of skin carcinogenesis. Biochimie. 2013;95:1171-1176. doi: 10.1016/j.biochi.2013.01.001


  1. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The world health organization/International society of urological pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998;22:1435-1448. doi: 10.1097/00000478-199812000-00001


  1. Fávaro WJ, Alonso JC, De Souza BR, et al. New synthetic nano-immunotherapy (OncoTherad®) for non-muscle invasive bladder cancer: Its synthesis, characterization and anticancer property. Tissue Cell. 2023;80:101988. doi: 10.1016/j.tice.2022.101988


  1. Reis IB, Tibo LH, Socca EA, De Souza BR, Durán N, Fávaro WJ. OncoTherad® (MRB-CFI-1) nano-immunotherapy reduced tumoral progression in non-muscle invasive bladder cancer through activation of Toll-like signaling pathway. Tissue Cell. 2022;76:101762. doi: 10.1016/j.tice.2022.101762


  1. Cuezva JM, Chen G, Alonso AM, et al. The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis. Carcinogenesis. 2004;25:1157-1163. doi: 10.1093/carcin/bgh113


  1. O’Donnell MA. Practical applications of intravesical chemotherapy and immunotherapy in high-risk patients with superficial bladder cancer. Urol Clin North Am. 2005;32:121-131. doi: 10.1016/j.ucl.2005.01.003


  1. Lobo N, Martini A, Kamat AM. Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2022;22:361-370. doi: 10.1080/14737140.2022.2046466


  1. Böhle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol. 2003;170:964-969. doi: 10.1097/01.ju.0000073852.24341.4a


  1. Wood D. Tumors of the bladder. In: Wein AJ, Kavoussi LR, Partin AW, Peters CA, editors. Campbell-Walsh Urology. 11th ed. Philadelphia, PA: Elsevier; 2016.


  1. Lim HY, Ho QS, Low J, Choolani M, Wong KP. Respiratory competent mitochondria in human ovarian and peritoneal cancer. Mitochondrion. 2011;11:437-443. doi: 10.1016/j.mito.2010.12.015


  1. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005;202:654-662. doi: 10.1002/jcp.20166


  1. Bouchelouche K, Choyke PL. PET/CT in renal, bladder and testicular cancer. PET Clin. 2015;10:361-374. doi: 10.1016/j.cpet.2015.03.002


  1. Renner K, Bruss C, Schnell A, et al. Restricting glycolysis preserves T cell effector functions and augments checkpoint therapy. Cell Rep. 2019;29:135-150.e9. doi: 10.1016/j.celrep.2019.08.068


  1. Wang T, Gnanaprakasam JN, Chen X, et al. Inosine is an alternative carbon source for CD8+-T-cell function under glucose restriction. Nat Metab. 2020;2:635-647. doi: 10.1038/s42255-020-0219-4


  1. Zhang Y, Kurupati R, Liu L, et al. Enhancing CD8+ T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy. Cancer Cell. 2017;32:377-391.e9. doi: 10.1016/j.ccell.2017.08.004


  1. Fischer K, Hoffmann P, Voelkl S, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007;109:3812-3819. doi: 10.1182/blood-2006-07-035972


  1. Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev. 2007;26:299-310. doi: 10.1007/s10555-007-9064-0


  1. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006;9:425-434. doi: 10.1016/j.ccr.2006.04.023


  1. Kitamura H, Kakehi Y. Treatment and management of high-grade T1 bladder cancer: What should we do after second TUR? Jpn J Clin Oncol. 2015;45:315-322. doi: 10.1093/jjco/hyu219


  1. Gontero P, Sylvester R, Pisano F, et al. The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guerin. BJU Int. 2016;118:44-52. doi: 10.1111/bju.13354


  1. Moschini M, Sharma V, Dell’oglio P, et al. Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy. BJU Int. 2016;117:604-610. doi: 10.1111/bju.13146
Conflict of interest
The authors declare that they have no competing interests.
Back to top
Tumor Discovery, Electronic ISSN: 2810-9775 Published by AccScience Publishing